- First prescriptions for Khiron's medical cannabis in
Peru are filled as the Company
surpasses 3,000 medical cannabis prescription milestone in
Colombia
- Khiron becomes the first Company to sell and fill medical
cannabis prescriptions through private pharmacies in Peru
- The Company began sales in Peru with full spectrum High CBD supplied by
Khiron Colombia and distributed to patients under the previously
announced agreement with Farmacia Universal S.A.C.
- Farmacia Universal is an established pharmacy chain, with 10
locations in Lima
- Quotas for Khiron's high THC medical cannabis have also been
approved by DIGEMID, Peru's drug
regulatory authority, with first prescriptions anticipated in Q4
2020
- With a population of 32 million, Peru's medical cannabis market is expected to
be one of the largest in Latin
America
TORONTO, Sept. 24, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced that it has filled the first
prescriptions of full spectrum, high CBD medical cannabis to
patients in Peru. This comes
following authorization from DIGEMID, Peru's drug regulatory authority,
and expands sales of Khiron's medical cannabis to a second
jurisdiction in Latin America,
following established sales in Colombia, where over 3,000 prescriptions have
been filled to date.
"After completing successfully all export, import and
distribution requirements to bring our approved high CBD medical
cannabis products into Peru, we
are now very proud to begin sales and give patients greater access
to medical cannabis therapies in order to improve significantly
their quality of life," comments Luis
Marquez, Khiron Peru Country Manager.
In Peru, only registered pharmaceutical establishments that
have received Good Storage Practices (GSP) certification and
licenses to import and commercialize medical cannabis are
authorized to participate in the wholesale import and
commercialization of cannabis products. Khiron Peru is a GSP
certified, registered pharmaceutical establishment, and Farmacia
Universal has all required permits and licenses, including Good
Manufacturing Practices (GMP) certification, to prepare magistral
preparations with medical cannabis and distribute final products to
patients through pharmacies under the previously announced
agreement with Khiron.
"At Khiron we continue to execute on our stated strategy to
deliver quality medical cannabis products to patients and to
improve the quality of their lives. In a short period of time, and
despite a global pandemic, we have filled over 3,000 medical
cannabis prescriptions in Colombia, and today we are pleased to expand
that reach, filling our first patient prescriptions in Peru, an important market of 32 million
people," comments Alvaro Torres,
Khiron CEO and director.
Additionally, quotas for Khiron's high THC medical cannabis
product in Peru have also been
approved by DIGEMID, with first patient prescriptions anticipated
to be filled in Q4 2020.
Farmacia Universal S.A.C. is a well-known Peruvian pharmacy
chain. The company operates ten locations in Lima and is a leader in the pharmaceutical
preparations sector in Peru. In
addition to selling pharmaceutical, surgical and orthopedic
products, among others, the company differentiates its brand with
premium service to customers and patients.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with Kuida™
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-becomes-first-company-to-sell-medical-cannabis-in-peru-and-surpasses-3-000-prescriptions-in-colombia-301137757.html
SOURCE Khiron Life Sciences Corp.